Insider Buying at Neuronetics: A Signal of Confidence?
On July 14, 2026, director Chernett Jorey added 35,000 shares to her Neuronetics portfolio at an average price of $1.78. The purchase brings her holdings to just over 10.6 million shares, roughly 8.5 % of the outstanding equity. The transaction occurs amid a broader wave of insider purchases—most notably the recent $1.86 buy by the company’s EVP and General Manager, Cory Anderson—suggesting that key stakeholders are betting on a rebound in the company’s valuation.
Implications for Investors
Neuronetics has endured a volatile year, sliding from a 52‑week high of $4.85 to a low of $0.80, and its price has declined 53.8 % over the last 12 months. Yet the recent flurry of insider buying, coupled with a 14.94 % weekly gain and a 39.37 % monthly rally, indicates that insiders may be expecting a sustained turnaround. For investors, the pattern of large, incremental purchases—often at or slightly above market price—can be interpreted as a signal of conviction rather than opportunistic speculation. However, the company’s negative P/E ratio (-3.21) and the absence of recent earnings guidance caution against taking this activity at face value without a clear view of the company’s cash flow prospects.
What Could Drive the Shift?
Several factors may be at play. Neuronetics has recently announced a new therapeutic platform for chronic neuro‑disorders, and its pipeline includes a late‑stage clinical trial that is expected to generate regulatory approval in the next 12–18 months. The timing of the insider purchases aligns with the release of preliminary trial data that was positive but not yet disclosed publicly. Moreover, the company’s recent restructuring of its executive compensation, with a larger portion of rewards tied to performance‑based units, may create a short‑term incentive for executives to boost share prices to meet vesting thresholds.
Profile of Chernett Jorey
Chernett’s transaction history since early 2026 shows a consistent pattern of large, regular purchases. From March to July, she bought a cumulative 2.4 million shares, averaging about 300,000 shares per month, typically at prices ranging from $1.17 to $1.58. Her most recent purchase of 35,000 shares at $1.78 represents a modest uptick in price relative to her historical average, indicating that she may be positioning for a short‑term upside. Her holdings have steadily grown to 10.6 million shares, underscoring a long‑term stake in the company. While she has not sold any shares in the past six months, the absence of any divestitures reinforces her bullish stance.
Takeaway for Market Participants
The current insider buying spree, led by Chernett and complemented by Anderson’s larger block, signals that the company’s top management believes Neuronetics is on a path to recover its valuation. For investors, the key is to monitor the progress of the clinical pipeline, any forthcoming earnings reports, and the company’s ability to convert these insider signals into tangible shareholder value. In an industry where therapeutic breakthroughs can trigger rapid valuation shifts, the insider activity may well be an early barometer for the next upside.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-07-14 | Chernett Jorey () | Buy | 35,000.00 | 1.78 | Common Stock |
